EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 11th, 2015 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
This Exclusive License Agreement (“Agreement”) is entered into and effective as of March 5, 2015 (“Effective Date”), by and between Navidea Biopharmaceuticals, Inc., a company organized and existing under the laws of Delaware, with its principal place of business located at 5600 Blazer Parkway, Suite 200, Dublin, OH 43017, (“Company”); SpePharm AG, a company organized and existing under the laws of Switzerland, with offices located at Kapellplatz 1, 6004 Luzern, Switzerland (“SpePharm”) and, solely for the purposes of Section 2.6 and Articles 14, 16 and 17, Norgine BV, a company organized and existing under the laws of The Netherlands, with offices located at Hogehilweg 7, 1101 CA Amsterdam Zuid-Oost, The Netherlands (“Norgine”). Company and SpePharm are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
